Search Result
Results for "
fibrinolytic
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P2373
-
|
|
Others
|
Cardiovascular Disease
|
|
Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases .
|
-
-
- HY-B1399
-
|
o-Cresotic acid; Hydroxytoluic acid
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
3-Methylsalicylic acid is a salicylic acid derivative that acts on human plasma and has significant fibrinolytic activity by activating the fibrinolytic system.
|
-
-
- HY-W012997
-
|
δ-valerolactone
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Tetrahydro-2H-pyran-2-one (δ-valerolactone) is an endogenous metabolite with antioxidant capacity. Tetrahydro-2H-pyran-2-one inhibits the proteolytic and fibrinolytic activities of human fibrinolytic protein .
|
-
-
- HY-122052
-
|
|
Others
|
Metabolic Disease
|
|
UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .
|
-
-
- HY-131409
-
|
D-Val-Leu-Lys-p-itoailide dihydrochloride; D-VLK-pNA dihydrochloride; S 2251 dihydrochloride
|
Fluorescent Dye
|
Others
|
|
D-Val-Leu-Lys-pNA dihydrochloride (D-VLK-pNA dihydrochloride) is a colorimetric substrate for plasminolytic activity. D-Val-Leu-Lys-pNA dihydrochloride is catalytically bound and hydrolyzed by plasmin to release p-nitroaniline (pNA), which can be detected colorimetrically at 405 nm as a measure of plasminolytic activity .
|
-
-
- HY-E70127
-
|
Brasan; Dasen
|
Others
|
Infection
|
|
Serratiopeptidase is an anti-inflammatory agent. Serratiopeptidase has anti-inflammatory, anti-biofilm, mucolytic, fibrinolytic, and wound-healing properties. Serratiopeptidase can be used for combat COVID-19-induced respiratory syndrome research .
|
-
-
- HY-E70393H
-
|
|
Others
|
Others
|
|
Human Factor XIIIa is a transglutaminase, which catalyzes the cross-linking of proteins and stabilizes the blood clots. Human Factor XIIIa protects the clots from degradation by fibrinolytic enzymes, which is important for maintaining hemostasis and preventing excessive bleeding .
|
-
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-157745
-
|
mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)
|
Biochemical Assay Reagents
|
Others
|
|
m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
|
-
-
- HY-P2970
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .
|
-
-
- HY-B0715
-
|
BL-191; PTX; Oxpentifylline
|
Phosphodiesterase (PDE)
Autophagy
HIV
|
Cardiovascular Disease
Cancer
|
|
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
|
-
-
- HY-129056
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .
|
-
-
- HY-17566
-
|
|
Antibiotic
Bacterial
|
Infection
Neurological Disease
Metabolic Disease
|
|
Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease .
|
-
-
- HY-B0715S
-
|
BL-191-d6; PTX-d6; Oxpentifylline-d6
|
Phosphodiesterase (PDE)
Autophagy
HIV
|
Cardiovascular Disease
Cancer
|
|
Pentoxifylline-d6 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
|
-
-
- HY-B0715S2
-
|
BL-191-d5; PTX-d5; Oxpentifylline-d5
|
Phosphodiesterase (PDE)
Autophagy
HIV
|
Cardiovascular Disease
Cancer
|
|
Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
|
-
-
- HY-B0715R
-
|
BL-191 (Standard); PTX (Standard); Oxpentifylline (Standard)
|
HIV
Autophagy
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Cancer
|
|
Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
|
-
-
- HY-129611
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
|
-
-
- HY-17566R
-
|
|
Antibiotic
Bacterial
|
Infection
Neurological Disease
Metabolic Disease
|
|
Capreomycin (sulfate) (Standard) is the analytical standard of Capreomycin (sulfate). This product is intended for research and analytical applications. Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-131409
-
|
D-Val-Leu-Lys-p-itoailide dihydrochloride; D-VLK-pNA dihydrochloride; S 2251 dihydrochloride
|
Dyes
|
|
D-Val-Leu-Lys-pNA dihydrochloride (D-VLK-pNA dihydrochloride) is a colorimetric substrate for plasminolytic activity. D-Val-Leu-Lys-pNA dihydrochloride is catalytically bound and hydrolyzed by plasmin to release p-nitroaniline (pNA), which can be detected colorimetrically at 405 nm as a measure of plasminolytic activity .
|
| Cat. No. |
Product Name |
Type |
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-131409
-
|
D-Val-Leu-Lys-p-itoailide dihydrochloride; D-VLK-pNA dihydrochloride; S 2251 dihydrochloride
|
Fluorescent Dye
|
Others
|
|
D-Val-Leu-Lys-pNA dihydrochloride (D-VLK-pNA dihydrochloride) is a colorimetric substrate for plasminolytic activity. D-Val-Leu-Lys-pNA dihydrochloride is catalytically bound and hydrolyzed by plasmin to release p-nitroaniline (pNA), which can be detected colorimetrically at 405 nm as a measure of plasminolytic activity .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0715S
-
|
|
|
Pentoxifylline-d6 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
|
-
-
- HY-B0715S2
-
|
|
|
Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-157745
-
|
mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
|
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
|
Polymers
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
